Lite Strategy, Inc. (LITS): Cash & Equivalents
$5.71M
As of 2026-06-30
-30.4%
3-year compound annual growth
-7.8%
5-year compound annual growth
-6.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $5.71M | -68.3% | 2026-09-28, Balance as of period end |
| 2025-06-30 | $18.01M | +386.1% | 2026-09-28, Balance as of period end |
| 2024-06-30 | $3.71M | -78.1% | 2025-09-26, Balance as of period end |
| 2023-06-30 | $16.91M | +7.4% | 2024-09-19, Balance as of period end |
| 2022-06-30 | $15.74M | +84.2% | 2023-09-26, Balance as of period end |
| 2021-06-30 | $8.54M | -30.7% | 2022-09-08, Balance as of period end |
| 2020-06-30 | $12.33M | +28.6% | 2022-05-23, Balance as of period end |
| 2019-06-30 | $9.59M | -27.9% | 2021-09-02, Balance as of period end |
| 2018-06-30 | $13.31M | +57.4% | 2020-09-09, Balance as of period end |
| 2017-06-30 | $8.46M | -22.0% | 2019-08-28, Balance as of period end |
| 2016-06-30 | $10.84M | -42.1% | 2018-08-30, Balance as of period end |
| 2015-06-30 | $18.72M | +35.9% | 2017-09-05, Balance as of period end |
| 2014-06-30 | $13.78M | -61.3% | 2016-09-06, Balance as of period end |
| 2013-06-30 | $35.57M | +473.6% | 2015-09-02, Balance as of period end |
| 2012-06-30 | $6.20M | +60.8% | 2014-09-09, Balance as of period end |
| 2011-06-30 | $3.86M | -57.3% | 2013-09-18, Balance as of period end |
| 2010-06-30 | $9.03M | n/a | 2012-09-18, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | 2026-06-30 | $5.71M | -68.3% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $27.14M | +20.8% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $28.41M | -4.8% |
| Medicinova Inc (MNOV) | 2025-12-31 | $30.81M | -23.7% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $40.99M | -41.3% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $30.15M | -34.9% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $968.0K | -87.9% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $41.30M | -41.9% |
| Theriva Biologics, Inc. (TOVX) | 2025-12-31 | $13.06M | +12.5% |
Compare LITS, CUE, BTAIQ, MNOV side by side · Screen every company in Pharmaceutical Preparations ↗